甘李藥業(603087.SH):GZR101中國I期臨牀試驗完成首例受試者給藥
格隆匯7月6日丨甘李藥業(603087.SH)公佈,公司自主研發的GZR101已經啟動中國I期臨牀試驗,於近日成功完成首例受試者給藥。
GZR101是甘李藥業在研的長效基礎胰島素GZR33與速效門冬胰島素混合製成的雙胰島素複方製劑,擬用於治療糖尿病。預期GZR101注射液在每日一次給藥的情況下能模擬生理性胰島素分泌的雙相模式,兼顧空腹和餐後血糖控制,平穩降糖,提高血糖控制達標率,同時簡化治療,提高患者依從性和降低治療負擔,優化糖尿病長期管理,有利於降低或延緩併發症的發生。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.